180 related articles for article (PubMed ID: 14872435)
1. Thromboelastography and recombinant factor VIIa-hemophilia and beyond.
Sørensen B; Ingerslev J
Semin Hematol; 2004 Jan; 41(1 Suppl 1):140-4. PubMed ID: 14872435
[TBL] [Abstract][Full Text] [Related]
2. Views on methods for monitoring recombinant factor VIIa in inhibitor patients.
Key NS; Nelsestuen GL
Semin Hematol; 2004 Jan; 41(1 Suppl 1):51-4. PubMed ID: 14872422
[TBL] [Abstract][Full Text] [Related]
3. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.
Sørensen B; Ingerslev J
J Thromb Haemost; 2004 Jan; 2(1):102-10. PubMed ID: 14717973
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
[TBL] [Abstract][Full Text] [Related]
5. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis.
Shima M
Semin Hematol; 2004 Jan; 41(1 Suppl 1):125-31. PubMed ID: 14872433
[TBL] [Abstract][Full Text] [Related]
6. Dose titration of recombinant factor VIIa using thromboelastograph monitoring in a child with hemophilia and high titer inhibitors to factor VIII: a case report and brief review.
Trowbridge CC; Stammers AH; Ciccarelli N; Klayman M
J Extra Corpor Technol; 2006 Sep; 38(3):254-9. PubMed ID: 17089513
[TBL] [Abstract][Full Text] [Related]
7. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing.
Abshire TC
Semin Hematol; 2004 Jan; 41(1 Suppl 1):3-7. PubMed ID: 14872413
[TBL] [Abstract][Full Text] [Related]
8. Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors.
Hedner U
J Thromb Haemost; 2006 Nov; 4(11):2498-500. PubMed ID: 16907841
[No Abstract] [Full Text] [Related]
9. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
Qi X; Zhao Y; Li K; Fan L; Hua B
Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
[TBL] [Abstract][Full Text] [Related]
10. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation.
Sørensen B; Johansen P; Christiansen K; Woelke M; Ingerslev J
J Thromb Haemost; 2003 Mar; 1(3):551-8. PubMed ID: 12871465
[TBL] [Abstract][Full Text] [Related]
11. Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.
Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Barrett JC; Ezban M
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):539-46. PubMed ID: 20581663
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B.
Fernández-Bello I; Stenmo C; Butta N; Lind V; Ezban M; Jiménez-Yuste V
Haemophilia; 2017 Nov; 23(6):868-876. PubMed ID: 28851065
[TBL] [Abstract][Full Text] [Related]
13. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects.
Sørensen B; Johansen P; Nielsen GL; Sørensen JC; Ingerslev J
Blood Coagul Fibrinolysis; 2003 Jul; 14(5):469-77. PubMed ID: 12851533
[TBL] [Abstract][Full Text] [Related]
14. Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients.
Viuff D; Andersen S; Sørensen BB; Lethagen S
Thromb Res; 2010 Aug; 126(2):144-9. PubMed ID: 20542542
[TBL] [Abstract][Full Text] [Related]
15. Comparison of kaolin and tissue factor activated thromboelastography in haemophilia.
Young G; Zhang R; Miller R; Yassin D; Nugent DJ
Haemophilia; 2010 May; 16(3):518-24. PubMed ID: 20028419
[TBL] [Abstract][Full Text] [Related]
16. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.
Sørensen B; Persson E; Ingerslev J
Br J Haematol; 2007 Apr; 137(2):158-65. PubMed ID: 17391496
[TBL] [Abstract][Full Text] [Related]
17. Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor.
Laguna P; Klukowska A
Haemophilia; 2005 Jan; 11(1):2-4. PubMed ID: 15660981
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial.
Young G; Ebbesen LS; Viuff D; Di Paola J; Konkle BA; Negrier C; Pasi J; Ingerslev J
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):276-82. PubMed ID: 18469548
[TBL] [Abstract][Full Text] [Related]
19. Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII.
Yoshioka A; Nishio K; Shima M
Haemostasis; 1996; 26 Suppl 1():139-42. PubMed ID: 8904189
[TBL] [Abstract][Full Text] [Related]
20. Variability of thromboelastographic responses following the administration of rFVIIa to haemophilia A dogs supports the individualization of therapy with a global test of haemostasis.
Othman M; Powell S; Hopman WM; Lillicrap D
Haemophilia; 2010 Nov; 16(6):919-25. PubMed ID: 20609015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
